- Home
- ATNM vs MDCX Comparison
ATNM vs MDCX Comparison
Compare ATNM & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- MDCX
- Stock Information
- Founded
- ATNM 2000
- MDCX 2008
- Country
- ATNM United States
- MDCX Canada
- Employees
- ATNM N/A
- MDCX N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- MDCX
- Sector
- ATNM Health Care
- MDCX
- Exchange
- ATNM Nasdaq
- MDCX Nasdaq
- Market Cap
- ATNM 51.5M
- MDCX 44.0M
- IPO Year
- ATNM N/A
- MDCX N/A
- Fundamental
- Price
- ATNM $1.52
- MDCX $2.52
- Analyst Decision
- ATNM Strong Buy
- MDCX Strong Buy
- Analyst Count
- ATNM 3
- MDCX 2
- Target Price
- ATNM $4.67
- MDCX $23.50
- AVG Volume (30 Days)
- ATNM 246.6K
- MDCX 426.1K
- Earning Date
- ATNM 08-04-2025
- MDCX 05-12-2025
- Dividend Yield
- ATNM N/A
- MDCX N/A
- EPS Growth
- ATNM N/A
- MDCX N/A
- EPS
- ATNM N/A
- MDCX N/A
- Revenue
- ATNM N/A
- MDCX N/A
- Revenue This Year
- ATNM N/A
- MDCX N/A
- Revenue Next Year
- ATNM N/A
- MDCX N/A
- P/E Ratio
- ATNM N/A
- MDCX N/A
- Revenue Growth
- ATNM N/A
- MDCX N/A
- 52 Week Low
- ATNM $1.03
- MDCX $1.80
- 52 Week High
- ATNM $8.64
- MDCX $8.94
- Technical
- Relative Strength Index (RSI)
- ATNM 42.39
- MDCX N/A
- Support Level
- ATNM $1.41
- MDCX N/A
- Resistance Level
- ATNM $1.95
- MDCX N/A
- Average True Range (ATR)
- ATNM 0.13
- MDCX 0.00
- MACD
- ATNM -0.04
- MDCX 0.00
- Stochastic Oscillator
- ATNM 6.54
- MDCX 0.00
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.